Veritas In Silico Inc.

Veritas In Silico (130A), founded in 2016 and headquartered in Shinagawa-ku, Tokyo, is a TSE Growth-listed company that operates in the pharmaceutical field. The company's business is characterized by providing mRNA-targeted small molecule drug discovery technology to pharmaceutical companies and earning contract fees from joint drug discovery research. In the disclosed consolidated businesses, drug discovery platform 100 (2025.12) is shown as the main business category. Company profile: Veritas In Silico Inc. (Veritas In Silico, English: Veritas In Silico Inc.) is a Japanese drug discovery biotechnology company. It has been reported that the two companies will conduct joint research and development using an AI platform and create an in-house development pipeline for drug discovery of nucleic acid drugs and small molecule drugs that target mRNA. Additionally, efforts to use low-molecular-weight compounds related to nucleic acid-targeted drug discovery have been reported. It was listed on the Tokyo Stock Exchange Growth Market in February 2024. When understanding the company's business content, it is easier to get a complete picture by looking at the company's main products and services, sales channels, customer base, and domestic and overseas expansion status.